Current Possibilities to Assess the Degree of Liver Fibrosis in Patients with Haemophilia Infected with HCV--Review

• Published in: Advances in clinical and experimental medicine : official organ Wroclaw Medical University Vol. 24; no. 4; pp. 671 - 677
• Main Authors: Kucharska, Marta, Inglot, Marcin, Kuliszkiewicz-Janus, Małgorzata, Pazgan-Simon, Monika, Knysz, Brygida
• Format: Journal Article
• Language: English
• Published: Poland 01.07.2015
• Subjects: Algorithms; Biomarkers - blood; Biopsy; Elasticity Imaging Techniques - methods; Hemophilia A - complications; Hemophilia A - therapy; Hepatitis C, Chronic - complications; Hepatitis C, Chronic - diagnosis; Hepatitis C, Chronic - transmission; Humans; Liver - metabolism; Liver - pathology; Liver Cirrhosis - blood; Liver Cirrhosis - diagnosis; Liver Cirrhosis - pathology; Liver Cirrhosis - virology; Predictive Value of Tests; Prognosis; Severity of Illness Index
• ISSN: 1899-5276
• DOI: 10.17219/acem/22913

Haemophilia is an entity, wherein the HCV infection rate is greater than in the general population and ranges between 70-90%. The majority of HCV infections were acquired by hemophiliacs in the 1980s, by the use of infected cryoprecipitate or fresh frozen plasma preparations. It is therefore highly likely that many of them, more than twenty years after the infection, have developed advanced liver disease. Until recently, in order to assess its severity, it was necessary to perform a liver biopsy. Currently, we observe rapid developments of non-invasive methods that are particularly useful in patients with bleeding disorders. The most popular include elastography (Fibroscan, SWE) and the algorithms based on measurements of the relevant blood parameters (e.g. FibroTest, Fibrometer, APRI index). Ease of implementation of these studies, no need for hospitalization of the patient or specific preparation for surgery, allow for quick and minimally invasive assessment of liver disease progression and classification of the patient to the appropriate antiviral therapy.